APOA1 related amyloidosis: a case report and literature review

Tisha Joy1, Jian Wang, Angelika Hahn

  • 1Robarts Research Institute, London, Ontario, Canada N6A 5K8.

Clinical Biochemistry
|November 26, 2003
PubMed
Abstract

Insights

Amyloidosis, caused by protein fibril deposition, can stem from rare apolipoprotein A-I (apoA-I) gene mutations. A G26R mutation in APOA1 was identified in a patient with kidney and nerve amyloidosis.

Area of Science:

  • Genetics
  • Biochemistry
  • Nephrology

Background:

  • Amyloidosis is characterized by extracellular deposition of insoluble protein fibrils.
  • This condition is linked to rare mutations in the apolipoprotein A-I (APO A1) gene.

Observation:

  • A patient presented with renal-predominant amyloidosis and neuropathy.
  • Genetic analysis revealed a specific mutation, G26R, in the APOA1 gene in this patient.

Findings:

  • The identified APOA1 G26R mutation is associated with amyloidosis.
  • While the exact mechanism remains unclear, this mutation contributes to the disease spectrum.

Implications:

  • Molecular diagnosis is crucial for differentiating APOA1-related amyloidosis from other genetic causes.
  • Understanding specific APOA1 mutations may inform clinical management and prognosis.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...